Depression and low testosterone are clinically connected in both directions. Testosterone acts on androgen receptors in limbic and prefrontal brain regions that regulate mood, motivation, and stress response. Deficiency in these pathways produces depressive symptoms that are often indistinguishable from primary major depressive disorder. At the same time, depression itself suppresses testosterone production through the HPA axis. This bidirectional loop means men with treatment-resistant depression or unexplained low mood should have testosterone levels evaluated, and that treating hypogonadism can meaningfully improve mood in men whose depression is driven by hormonal deficiency.
The Bidirectional Relationship: How Testosterone and Depression Drive Each Other
The connection between testosterone and mood is not simply that “low T causes depression.” The relationship is more complex and self-reinforcing: testosterone deficiency creates neurobiological conditions that promote depressive symptoms, and depression itself suppresses the hypothalamic-pituitary-gonadal (HPG) axis, further lowering testosterone. Men caught in this cycle may see neither condition improve if only one is addressed.
How low testosterone promotes depression
Testosterone acts on androgen receptors distributed throughout brain regions central to mood regulation — the hippocampus, amygdala, prefrontal cortex, and hypothalamus. Several mechanisms link low testosterone to depressive symptoms directly. Testosterone facilitates serotonin synthesis and increases the sensitivity of serotonin receptors; hypogonadal men show measurable reductions in serotonergic tone. Testosterone also modulates dopaminergic signaling in the mesolimbic pathway — the reward and motivation circuit. When testosterone falls, dopaminergic drive decreases, producing the anhedonia, low motivation, and emotional blunting that are core features of both hypogonadism and depression.
Additionally, low testosterone is associated with elevated neuroinflammatory markers. Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) — both elevated in hypogonadism — are independently associated with depressive disorders. The relationship between inflammation, testosterone deficiency, and depression is now a recognized research focus in neuroendocrinology.
How depression suppresses testosterone
The stress response system — the HPA axis — directly inhibits the HPG axis. Chronic psychological stress and depression elevate cortisol, which suppresses GnRH release from the hypothalamus, reduces LH secretion from the pituitary, and blunts Leydig cell response to LH stimulation in the testes. The net result is lower endogenous testosterone production. This mechanism explains why men with chronic depression or anxiety consistently show lower testosterone than age-matched healthy controls, independent of other variables.
In primary hypogonadism, the testes fail to produce testosterone despite adequate LH stimulation. In secondary hypogonadism, the HPG axis itself is suppressed. LH and FSH are low or low-normal, and testosterone is low. Men with chronic depression frequently present with secondary hypogonadism driven by chronic HPA activation. This distinction matters clinically: secondary hypogonadism often responds to treatment of the underlying stressor (including depression) as well as to direct HPG axis support.
Symptom Overlap: Why the Connection Is Missed
The symptoms of hypogonadism and major depressive disorder overlap so extensively that clinicians — and patients — routinely mistake one for the other, or fail to recognize that both are simultaneously present. This misattribution is one reason depression in men is both undertreated and frequently treated with the wrong intervention.
Symptom Overlap: Hypogonadism vs. Major Depressive Disorder
Many symptoms are clinically identical — only laboratory evaluation can distinguish them
The purple “shared” column contains 8 symptoms that appear in diagnostic criteria for both hypogonadism and MDD. A man presenting with these symptoms alone cannot be diagnosed with either condition without laboratory evaluation of testosterone, LH, and FSH.
What the Clinical Evidence Shows About TRT and Depression
The evidence base has grown substantially over the past two decades. The key findings from the highest-quality studies can be summarized as follows.
A 2009 meta-analysis by Zarrouf et al. in the Journal of Psychiatric Practice pooled data from randomized controlled trials and found that testosterone therapy significantly reduced depressive symptoms in men, with a substantially higher response rate in hypogonadal men (approximately 56%) compared to eugonadal men (approximately 20%). This finding is important: it establishes that testosterone’s antidepressant effect is not a general psychoactive effect — it is specific to men whose depression is driven by hormonal deficiency.
The 2016 Testosterone Trials (TTrials), published in NEJM, enrolled 790 symptomatic hypogonadal men aged 65 and older across multiple centers. The sexual function and vitality sub-studies showed statistically significant improvements in energy, mood, and motivation — though the sexual function trial’s mood findings were secondary endpoints. The TRAVERSE trial (2023, NEJM), which enrolled over 5,000 men and assessed cardiovascular safety of TRT, also documented consistent improvements in quality-of-life and mood scores among hypogonadal participants.
| Study | Population | Finding on Mood / Depression | Clinical Implication |
|---|---|---|---|
| Zarrouf et al., 2009 J Psychiatric Practice (meta-analysis) |
Hypogonadal and eugonadal men with depression | 56% response in hypogonadal vs. 20% in eugonadal men. Significant reduction in depressive symptom scores. | TRT’s mood benefit is specific to men with confirmed low testosterone |
| Pope et al., 2003 Am J Psychiatry (RCT) |
Hypogonadal men with treatment-resistant depression | Testosterone augmentation significantly improved depressive symptoms in men who had failed ≥2 antidepressants | Consider testosterone evaluation in treatment-resistant depression |
| Shores et al., 2004 Am J Geriatric Psychiatry |
Older men, community sample | Low testosterone independently predicted development of depression over 2-year follow-up (OR 2.1) | Hypogonadism is a prospective risk factor for depression — not only correlated |
| TTrials (Snyder et al.), 2016 NEJM |
790 men ≥65 with testosterone <275 ng/dL | Significant improvements in energy, vitality, and mood scores vs. placebo at 12 months | TRT improves mood-related quality of life in older hypogonadal men |
The evidence supports testosterone therapy for depression in men with confirmed hypogonadism. It does not support using testosterone to treat depression in men with normal testosterone levels. Studies of testosterone in eugonadal depressed men show minimal mood benefit and introduce unnecessary hormonal risk. Any man experiencing depressive symptoms, regardless of suspected testosterone level, should be evaluated by a qualified clinician. Suicidal ideation requires immediate psychiatric evaluation. Testosterone therapy is not a substitute for mental health care.
If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.
Who Is Most Likely to Benefit: Identifying Testosterone-Driven Depression
Not every depressed man has low testosterone, and not every man with low testosterone is depressed. The clinical profile most likely to benefit from testosterone evaluation and treatment has the following characteristics.
Men who present with depression alongside a constellation of physical hypogonadism symptoms — reduced libido, erectile dysfunction, reduced muscle mass, increased visceral fat — are strong candidates for testosterone evaluation. The presence of physical symptoms alongside mood symptoms suggests hormonal deficiency as a common driver, rather than a psychiatric illness independent of hormonal status. Similarly, men whose depression began in their late 30s or 40s — the age range when testosterone naturally begins to decline — without a prior psychiatric history warrant hormonal evaluation before or alongside antidepressant therapy.
Men with diabetes, obesity, obstructive sleep apnea, or opioid use — all established causes of secondary hypogonadism — are at particularly elevated risk. The overlap between metabolic disease, hormonal deficiency, and depression is well-documented and clinically underappreciated. Addressing testosterone deficiency in these men frequently produces improvements across all three domains simultaneously.
Clinical Pathway: Depression + Suspected Low Testosterone
TRT vs. Antidepressants: Not an Either/Or Decision
One of the most common misconceptions is that choosing TRT means forgoing antidepressant medication, or vice versa. The evidence does not support this framing. For many hypogonadal men with depression, both conditions require simultaneous treatment — particularly when depression is moderate to severe.
The practical clinical approach: if testosterone is confirmed low and depression is mild to moderate, a trial of TRT alone is reasonable, with reassessment at 8–12 weeks. If depression is severe — particularly if suicidal ideation is present — antidepressant therapy should begin concurrently or be prioritized. TRT’s mood effects take several weeks to manifest, and waiting for hormonal normalization in a severely depressed patient is not clinically appropriate.
Conversely, men whose antidepressants are partially effective — reducing depression from severe to moderate but not achieving remission — may find that testosterone optimization produces the additional improvement that medication alone could not. This augmentation pattern is supported by the Pope et al. (2003) data and is consistent with the known serotonergic and dopaminergic effects of testosterone.
Resistance training: Shown to increase testosterone by 15 to 25% acutely and improve depressive symptoms comparably to antidepressants in mild-moderate depression (Blumenthal et al. meta-analysis). The most impactful non-pharmacologic intervention for both conditions simultaneously.
Sleep optimization: 70% of daily testosterone production occurs during sleep, with most secreted during slow-wave sleep. Untreated sleep apnea, common in overweight men, suppresses testosterone by 10 to 15% and independently worsens depression. Addressing sleep hygiene and obtaining a sleep study if indicated is high-yield.
Body fat reduction: Visceral adipose tissue converts testosterone to estradiol via aromatase. Reducing body fat through diet, exercise, and if appropriate, supervised weight loss pharmacotherapy, increases bioavailable testosterone and reduces the inflammatory burden that drives both hypogonadism and depression.
Alcohol reduction: Chronic alcohol use suppresses LH secretion and directly impairs Leydig cell function. Reducing alcohol intake is one of the most modifiable contributors to both low testosterone and poor mood.
Getting Evaluated: What Labs to Request and How to Interpret Them
Testosterone testing requires attention to timing and methodology. Total testosterone follows a circadian pattern, peaking in the early morning and declining through the day. A sample drawn at 3 PM may be 20–30% lower than a morning draw in the same individual — and may be misinterpreted as hypogonadal when it is not. All testosterone testing should be performed between 8 and 10 AM, fasting, on two separate days before a diagnosis of hypogonadism is made per Endocrine Society guidelines.
| Test | Why It Matters for Depression + Low T | Action Threshold |
|---|---|---|
| Total Testosterone | Primary diagnostic marker. Must be drawn fasting, 8–10 AM, confirmed on two separate days. | <300 ng/dL on two draws = hypogonadism per Endocrine Society |
| Free Testosterone | Biologically active fraction. Men with high SHBG may have normal total T but low free T — and symptoms. | <5–9 pg/mL (lab-dependent); calculate via SHBG + albumin if direct assay unavailable |
| LH / FSH | Distinguishes primary (elevated LH/FSH) from secondary (low/normal LH/FSH) hypogonadism. Secondary is more common in depression. | Low LH with low T = secondary hypogonadism — consider pituitary evaluation |
| SHBG | Sex hormone-binding globulin reduces free testosterone. Elevated by aging, liver disease, hyperthyroidism. | High SHBG with borderline total T may explain symptoms despite “normal” total testosterone |
| Prolactin | Elevated prolactin suppresses GnRH and causes secondary hypogonadism. Also associated with low mood. | >20 ng/mL warrants MRI pituitary to rule out prolactinoma |
| TSH | Hypothyroidism produces fatigue, depression, and low libido — closely mimics hypogonadism. | TSH >4.0 mIU/L requires follow-up Free T4 and clinical evaluation |
Laboratory reference ranges for testosterone (typically 300 to 1,000 ng/dL) are derived from population distributions and include a wide range of ages and health statuses. A 45-year-old man with a testosterone of 310 ng/dL is technically within range but may be functioning at the bottom 5th percentile for his age cohort. Symptomatic hypogonadism is a clinical diagnosis. Labs inform but do not replace clinical judgment. Men with levels in the 300 to 400 ng/dL range who have significant symptoms warrant a clinical conversation about treatment, not automatic reassurance.
Start With a Clinical Evaluation
If you are experiencing persistent low mood, fatigue, reduced motivation, or other symptoms that overlap with both depression and hypogonadism, the first step is a comprehensive hormonal and metabolic evaluation — not a trial of antidepressants in the absence of lab data, and not self-treatment with over-the-counter testosterone products. Advanced TRT Clinic provides physician-supervised testosterone therapy via telemedicine, including baseline lab coordination, clinical interpretation, and ongoing management. Availability varies by state.
